Evaluation of the Efficacy of Corticosteroids in Septic Arthritis in Adults
ConditionSeptic Arthritis
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
Septic arthritis is a severe infection associated with significant morbidity and mortality. Despite eradication of the microorganisms, persistent inflammation may lead to substantial long-term functional joint sequelae. The use of corticosteroids could reduce this inflammation, thereby improving functional joint outcomes and facilitating first-line medical treatment. The hypothesis of this study is that corticosteroid administration, in addition to antibiotic therapy, reduces persistent inflammation and improves functional joint prognosis in adult patients with acute septic arthritis.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Documented septic arthritis (microorganism identified intra-articularly by culture or PCR, or by turbid synovial fluid with positive Gram stain, or positive blood cultures)
Effective antibiotic therapy initiated within ≤ 3 days
Effective contraception for women of childbearing age during treatment period
Disqualifiers
Polyarticular septic arthritis (≥ 2 joints)
Septic arthritis of small joints (e.g., fingers: proximal interphalangeal joint (PIP), distal interphalangeal joints (DIP), MetaCarpoPhalangeal (MCP); toes: MTP)
Systemic sclerosis
Pyomyositis
Trial design
Treatments tested in this trial
- oral prednisone or placebo at a dose of 60 mg per day for 7 days
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov